Neonatal neuronal WWOX gene therapy rescues Wwox null phenotypes

Srinivasarao Repudi, Irina Kustanovich, Sara Abu-Swai, Shani Stern, Rami I. Aqeilan

Research output: Contribution to journalArticlepeer-review

Abstract

WW domain-containing oxidoreductase (WWOX) is an emerging neural gene-regulating homeostasis of the central nervous system. Germline biallelic mutations in WWOX cause WWOX-related epileptic encephalopathy (WOREE) syndrome and spinocerebellar ataxia and autosomal recessive 12 (SCAR12), two devastating neurodevelopmental disorders with highly heterogenous clinical outcomes, the most common being severe epileptic encephalopathy and profound global developmental delay. We recently demonstrated that neuronal ablation of murine Wwox recapitulates phenotypes of Wwox-null mice leading to intractable epilepsy, hypomyelination, and postnatal lethality. Here, we designed and produced an adeno-associated viral vector (AAV9) harboring murine Wwox or human WWOX cDNA and driven by the human neuronal Synapsin I promoter (AAV-SynI-WWOX). Testing the efficacy of AAV-SynI-WWOX delivery in Wwox-null mice demonstrated that specific neuronal restoration of WWOX expression rescued brain hyperexcitability and seizures, hypoglycemia, myelination deficits, and the premature lethality and behavioral deficits of Wwox-null mice. These findings provide a proof-of-concept for WWOX gene therapy as a promising approach to curing children with WOREE and SCAR12.

Original languageEnglish
Article numbere14599
JournalEMBO Molecular Medicine
Volume13
Issue number12
DOIs
StatePublished - 7 Dec 2021

Bibliographical note

Funding Information:
We would like to thank all members of the Aqeilan?s laboratory for technical help and fruitful discussion. Special thanks go to all WOREE and SCAR12 syndrome patients and families and WWOX foundation for their continuous support. The Aqeilan?s laboratory is funded by the European Research Council (ERC) [No. 682118] and Proof-of-concept ERC grant [No. 957543]. Shani Stern is supported by the Zuckerman STEM Leadership Program.

Funding Information:
We would like to thank all members of the Aqeilan’s laboratory for technical help and fruitful discussion. Special thanks go to all WOREE and SCAR12 syndrome patients and families and WWOX foundation for their continuous support. The Aqeilan’s laboratory is funded by the European Research Council (ERC) [No. 682118] and Proof‐of‐concept ERC grant [No. 957543]. Shani Stern is supported by the Zuckerman STEM Leadership Program.

Publisher Copyright:
© 2021 The Authors. Published under the terms of the CC BY 4.0 license.

Keywords

  • AAV9
  • DEE28
  • WOREE syndrome
  • hypomyelination
  • seizures

ASJC Scopus subject areas

  • Molecular Medicine

Fingerprint

Dive into the research topics of 'Neonatal neuronal WWOX gene therapy rescues Wwox null phenotypes'. Together they form a unique fingerprint.

Cite this